New RNA-editing tools expand therapeutic toolkits
Improved chemistry may make RNA editing therapies more feasible in humans.
gene editing
CRISPR for Vaccine Development
Discover a novel approach to vaccine discovery using CRISPR engineering.
Multiple mutations may no longer stump gene therapies
Creative solutions may enable gene therapy for more common diseases.
On the road to treating mitochondrial disease
Recent advancements in mitochondrial genome editing technologies take scientists one step closer to developing viable treatments for mitochondrial diseases, which affect 1 in 4300 adults.
Infographic: CRISPR editing for treating Duchenne muscular dystrophy
Researchers are using CRISPR gene editing to restore function of the mutant protein that causes Duchenne muscular dystrophy, a genetic disease that causes muscle degeneration.
In Vivo CRISPR Gene Editing for Genetic Disorders
LIVE October 25th, 2021 at 1:00 PM ET
Delivering CRISPR cargo in vivo to treat disease-causing DNA mutations
Delivering CRISPR cargo in vivo to treat disease-causing DNA mutations
CRISPR advances cardiovascular disease research
CRISPR gene editing directly and indirectly drives advances in cardiovascular disease therapeutic development.
Keolu Fox revises historical narratives with genome data
A native Hawaiian, anthropologist, and genome scientist, Keolu Fox investigates how mutations found in indigenous populations contribute to human health and emphasizes the importance of considering who benefits from research involving indigenous genomes.
On Target: Understanding Base Editors
LIVE July 28th, 2021 at 2:30 PM ET
In this webinar, experts will discuss cytosine and adenosine base-editors to introduce point mutations in DNA strands without creating a breakpoint, and opportunities and considerations for using them.
In this webinar, experts will discuss cytosine and adenosine base-editors to introduce point mutations in DNA strands without creating a breakpoint, and opportunities and considerations for using them.
Patent Docs: Patent interference parties provide evidence for priority
The arguments over "first to invent" and ownership of CRISPR tech continue
